10 results
Keyword ipilimumab Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Yervoy
Ipilimumab, Melanoma
Date of authorisation: 12/07/2011, Revision: 31, Authorised, Last updated: 27/01/2020Yervoy, INN-ipilimumab 30 Churchill Place … authorisation) Yervoy ipilimumab On 26 April 2018, the Committee … combination of nivolumab with ipilimumab is established only in patients … -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015,
, Revision: 30, Authorised, Last updated: 30/01/2020
another cancer medicine, ipilimumab, to treat adults whose cancer … used in combination with ipilimumab (another cancer medicine … alone or in combination with ipilimumab. The doctor may need to delay … -
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015,, Revision: 24, Authorised, Last updated: 11/12/2019
Keytruda or another medicine, ipilimumab. Patients treated with Keytruda … compared with 2.8 months with ipilimumab. Also, up to 74% of patients … compared with 59% of patients on ipilimumab. A third study in 1,019 patients … -
List item
Human medicine European public assessment report (EPAR): Mekinist
trametinib, Melanoma
Date of authorisation: 30/06/2014, Revision: 18, Authorised, Last updated: 04/02/2020 -
List item
Human medicine European public assessment report (EPAR): Tafinlar
dabrafenib mesylate, Melanoma
Date of authorisation: 26/08/2013, Revision: 21, Authorised, Last updated: 17/01/2020 -
List item
Human medicine European public assessment report (EPAR): Cotellic
cobimetinib hemifumarate, Melanoma
Date of authorisation: 20/11/2015,, Revision: 7, Authorised, Last updated: 20/08/2019
-
List item
Human medicine European public assessment report (EPAR): Zelboraf
vemurafenib, Melanoma
Date of authorisation: 17/02/2012, Revision: 19, Authorised, Last updated: 30/01/2020 -
List item
Human medicine European public assessment report (EPAR): Yescarta
axicabtagene ciloleucel, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018,, 
, Revision: 4, Authorised, Last updated: 03/02/2020
-
List item
Human medicine European public assessment report (EPAR): Tecentriq
atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/09/2017,, Revision: 6, Authorised, Last updated: 23/10/2019
-
List item
Human medicine European public assessment report (EPAR): Nivolumab BMS
nivolumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/07/2015, Withdrawn, Last updated: 14/01/2016